1 000+ Gene Therapy Industry reports covering 200 countries — revenue data, market shares and forecast 2026-2030.
Global gene therapy market projected from $9.8B in 2025 to $23B by 2030. Novartis, Gilead, Roche and Sarepta hold leading approved-therapy share. Full report covers production data and forecasts across 2026-2030.
North America gene therapy market estimated at $5.6B in 2025, 19.1% CAGR. US and Canadian pipelines led by Novartis, Sarepta, Vertex and Pfizer. Includes economic analysis, infrastructure and forecasts to 2030.
US gene therapy market estimated at $5.2B in 2025, growing 19.4% annually. Novartis, Sarepta, Bluebird Bio and Vertex lead FDA-approved portfolios. Details production capacity, infrastructure and forecasts for 2026-2030.
Europe gene therapy market forecast to reach $6.4B by 2030 at 17.5% CAGR. Novartis, Orchard and uniQure lead EMA-approved product market share. Covers market size, infrastructure plans and sales data for 2026-2030.
Asia gene therapy market forecast to grow from $2.1B to $5.4B by 2030. Profiles JW Therapeutics, Legend Biotech, Astellas and 20+ regional players. Includes infrastructure outlook, product launches and forecasts to 2030.
UK gene therapy market valued at $610M in 2025, growing 18.1% annually. Oxford Biomedica, GSK and Orchard drive market share and M&A activity. Report covers share analysis, client wins and forecasts to 2030.
96%
of our customers give us a high rating on Trustpilot and G2 platforms